Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
Zhaohui Leng
ResearcherPublications, citations & collaboration network
Zhaohui Leng is a researcher indexed in ScholarIQ from OpenAlex & ORCID. ScholarIQ records 7 works, 53 citations, an h-index of 4 and an i10-index of 3.
7
Works
53
Citations
4
h-index
3
i10-index
IDs:OpenAlex
How has Zhaohui Leng's publication output changed over time?
ScholarIQpublication output · 2022–2023
Output grew33% over the shown period — from 3 works in 2022 to 4 in 2023.
3
4
20222023
What are the most-cited papers on Zhaohui Leng?
ScholarIQmost cited works
LPCAT1 promotes gefitinib resistance via upregulation of the EGFR/PI3K/AKT signaling pathway in lung adenocarcinoma
Jianghua Ding, Xinjing Ding, Zhaohui Leng
S200072998. 202220 CitationsOPEN ACCESS
Etoposide/platinum plus anlotinib for patients with transformed small-cell lung cancer from EGFR-mutant lung adenocarcinoma after EGFR-TKI resistance: a retrospective and observational study
Jianghua Ding, Zhaohui Leng, Hong Gu, Jing Xiang, Yun Song
Frontiers in Oncology. 202314 CitationsOPEN ACCESS
Immunotherapy-based therapy as a promising treatment for EGFR-mutant advanced non-small cell lung cancer patients after EGFR-TKI resistance
Jianghua Ding, Xinjing Ding, Zhaohui Leng
S93370067. 202311 Citations
Aumolertinib challenge as an optional treatment in advanced non small‑cell lung cancer after osimertinib failure with epidermal growth factor receptor‑sensitive mutation: A case series
Xinjing Ding, Jianghua Ding, Zhaohui Leng, Yun Song
Oncology Letters. 20225 CitationsOPEN ACCESS
A novel prednisone premedication protocol significantly decreases infusion‑related reactions of rituximab in newly diagnosed diffuse large B‑cell lymphoma
Jianghua Ding, Zhaohui Leng, Hong Gu, Jing Xiang
Oncology Letters. 20233 CitationsOPEN ACCESS
Related on ScholarIQ
Jiujiang University
Institution
LPCAT1 promotes gefitinib resistance via upregulation of the EGFR/PI3K/AKT signaling pathway in lung adenocarcinoma
Paper
Etoposide/platinum plus anlotinib for patients with transformed small-cell lung cancer from EGFR-mutant lung adenocarcinoma after EGFR-TKI resistance: a retrospective and observational study
Paper
Immunotherapy-based therapy as a promising treatment for EGFR-mutant advanced non-small cell lung cancer patients after EGFR-TKI resistance
Paper
Aumolertinib challenge as an optional treatment in advanced non small‑cell lung cancer after osimertinib failure with epidermal growth factor receptor‑sensitive mutation: A case series
Paper
A novel prednisone premedication protocol significantly decreases infusion‑related reactions of rituximab in newly diagnosed diffuse large B‑cell lymphoma
Paper